Novartis shares jump as cancer drug shows promise (AP)
Shares of drug developer Novartis AG jumped Monday after the company said its kidney cancer drug candidate delayed tumor growth twice as long as placebo in a late-stage study.
Insurances & Business
News Economy Business Investment Banks Credits
Leave a Reply »»
Similar/Related/News:
- Celebrex Shows Promise in Lung Cancer Prevention CHICAGO (Reuters) - A high dose of the arthritis drug Celebrex showed early signs that it may help prevent lung cancer in heavy smokers, U.S. rese...
- Cephalon shares fall ahead of FDA panel on pain drug Fentora (AP) Cephalon Inc. shares fell Friday over concerns that the biotechnology company may face a tougher-than-expected Food and Drug Administration panel revi...
- Merck shares fall on FDA drug rejection, Abbott shares rise (AP) Merck & Co. shares fell Tuesday after the Food and Drug Administration rejected the drugmaker's cholesterol drug Cordaptive, marking the company's sec...
- ImClone Shares Rise on Pipeline Advance (AP) Shares of ImClone Systems Inc. rose Thursday following the biotechnology company's announcement it will move a head-and-neck cancer drug candidate int...
- Movers roundup: Avant, Cypress Semiconductor (AP) Shares of Avant Immunotherapeutics Inc. are climbing after the company licensed a cancer vaccine candidate to drug developer Pfizer....
- Human Genome Sciences shares fall on drug candidate swap (AP) Shares of Human Genome Sciences fell Thursday after the biotechnology company bought back the rights to its cancer treatments, a move one analyst said...
- Takeda says to buy Millennium Pharma for $8.8 billion (Reuters) Takeda Pharmaceutical Co Ltd said it would buy U.S. firm Millennium Pharmaceuticals Inc for $8.8 billion to boost its cancer drug business, in the big...
- Takeda Says to Buy Millennium Pharma For $8.8 Billion TOKYO (Reuters) - Takeda Pharmaceutical Co Ltd <4502.T> said it would buy U.S. firm Millennium Pharmaceuticals Inc <MLNM.O> for $8.8 b...